Categorized | Stock Newsletters
SKTO Has Enormous Growth Strategy Including Stem Cell Technology
Posted on 15 March 2010 by admin
The growth potential of SK3 Group, Inc. (OTCBB: SKTO) is enormous because:
(1) industry it operates within
(2) the aggressive acquisition path the Company is pursuing
Hence, the events in the near and mid-term could prove interesting.
I believe SKTO has been on a well engineered rollup strategy that is poised to propel the stock to much higher levels in the coming days, weeks and months.
Key 5 Developments: Rapid Growth Through Acquisitions
In the last few months SK3 and its parent Healthcare of Today has made a number of acquisitions to grow its business. The company realizes the need to expand its product and service portfolio and the need to have a diverse range of services to grow steadily and service its patients better. All the acquisitions are strategic in nature and will enable SK3 to emerge as a complete and grow faster than its peers and create value for its shareholders in the long term.
- DyfucaMed®, LLC. SK3 Group, Inc.'s parent company, Healthcare of Today, Inc. has signed a letter of intent with leading edge medical product company DyfucaMed®, LLC. The agreement will allow Healthcare of Today, Inc. to offer DyfucaMed®’s line of products to its patients.
This is a major event for SK3 Group, Inc. as with this new agreement in place, the company will be able to leverage DyfucaMed®’s cutting-edge line of products and offer better treatment to millions of patients and thereby grow the business.
The company plans to also work closely with DyfucaMed® on the innovation and development of various new drugs based on stem cell technology and controlled application of a concentrated platelet gel. With demand for such drugs growing multi-fold and the aging population of US and need for aggressive recovery is the stock of the future with considerable growth potential.
- Xenotis Pty Ltd. In Dec 2009, SK3 Group, Inc.'s parent, Healthcare of Today, Inc. acquired Xenotis Pty Ltd., the Australian-based producer of advanced human tissue engineering technology for $40Million.
Xenotis is a leader in the world in advanced human tissue engineering. While many companies are interested in this fast-growing market, few have made the clear strides that Xenotis has. The company has working products and a strong distribution network in place around the globe. There is a particular dynamic to be enjoyed by SK3 given its relationship with Regenetech, which is the world leader in advanced stem cell research technology.
- NuvoDigital Technology, Inc: SK3 Group, Inc., recently, announced that its parent, Healthcare of Today, Inc. has acquired NuvoDigital Technology, Inc., a data security technology firm based in Salt Lake City. NuvoDigital Technology, Inc.'s technology explores the realm of complete, digital data protection from unauthorized use, with an emphasis on meeting the industry standards for HIPAA compliant data security technology.
NuvoDigital provides exceptional data security capabilities, and is a natural fit for healthcare companies like Healthcare of Today, which want to protect its patients' private information. As its own Healthcare of Today network continues to grow, it is important to think not only about how it is providing healthcare services and products to its patients on a daily basis, but how it protects them long after they leave its offices.
- Prescient Global, Inc. Earlier, Healthcare of Today had acquired Prescient Global, Inc., the global security division of Prescient Edge Consulting, which offers complete solutions for corporate security, protecting personnel, assets, and interests in a changing global marketplace. Through its work, Prescient Global is able to assist companies in increasing product value, company profitability, and ultimately, shareholder peace of mind.
- MacuCLEAR, Inc. In Jan 2010, SK3 Group, Inc.’s parent, Healthcare of Today, Inc., has entered into a letter of intent to acquire MacuCLEAR, Inc., a pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye. If the company goes ahead and completes this acquisition then it will mark the entry of SK3 in to the vast eye-care industry.
------------------------------------------------------------
Clearly, SK3 has made some high-stake deals in the medical fields!
I feel the company is making the right moves and if it is able to complete these acquisitions and integrate them with itself, SK3 could be emerge as a significant player in the modern healthcare market.
So, if the company is able to strike a few more deals of similar nature, which by the company is working on then it could be a sure shot multi-bagger as it will then move into the league of the major bio-tech firms.Watch SKTO trade and don't miss out!
Best Regards,
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. ****************************************************************************************************************** The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: The SuperHotPennyStocks employees are not Registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://www.superhotpennystocks.com/disclaimer Release of Liability: Through use of this website viewing or using you agree to hold SuperHotPennyStocks, its operators owners and employees harmless and to compltely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury
(monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SuperHotPennyStocks's affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SuperHotPennyStocks encourages readers and investors to supplement the information in these reports with independent research and other pro advice. SuperHotPennyStocks encourages readers and investors to supplement the information in these reports with independent research and other pro advice. SuperHotPennyStocks has agreed to be compensated seventy five thousand dollars and is negotiating for an additional fifty thousand dollars by a third party Creme Dellatex for a two week investor
awareness marketing campaign on SKTO. All information on featured companies is provided by the companies profiled, or is available from public sources and SuperHotPennyStocks makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to or sell any securities. Any claims or Statements should be deemed apocryphal. SuperHotPennyStocks, nor any of its affiliates are not registered investment advisors or a broker dealers.
|
|